Edwards Lifesciences Corporation
EW
$86.67
-$0.08-0.09%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 25.71% | -26.90% | -21.50% | -21.29% | -23.96% |
| Total Depreciation and Amortization | 36.32% | -22.68% | -19.84% | -16.70% | -20.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 205.34% | 108.91% | 18.53% | 27.24% | 61.86% |
| Change in Net Operating Assets | 19.13% | -6.69% | 33.55% | -79.16% | -76.13% |
| Cash from Operations | 26.09% | -8.22% | 65.88% | -39.46% | -22.61% |
| Capital Expenditure | 11.05% | 47.30% | 25.55% | 20.75% | -2.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -748.26% | -748.26% | -748.26% | -213.24% | 132.58% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -246.96% | -138.98% | -72.54% | -78.95% | -37.22% |
| Cash from Investing | -137.58% | 600.41% | 887.77% | 1,230.78% | 1,041.39% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 13.90% | -26.09% | -30.14% | -14.66% | -8.89% |
| Repurchase of Common Stock | -40.58% | 59.77% | 25.96% | 81.99% | 53.23% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2,703.33% | -70.49% | 447.83% | 646.15% | 400.00% |
| Cash from Financing | 35.65% | -95.03% | -194.26% | -38.26% | -25.40% |
| Foreign Exchange rate Adjustments | -92.44% | -91.76% | 104.23% | 436.31% | 1,685.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -143.56% | 167.26% | 444.47% | 409.00% | 1,299.20% |